Drug-loaded artificial pericardium and preparation method thereof

Abstract

The invention relates to the technical field of medical materials, in particular to a drug-loaded artificial pericardium and a preparation method thereof. The drug-loaded artificial pericardium provided by the invention can be used for relieving adhesion between the heart and surrounding tissues after cardiac surgery and relieving postoperative inflammatory reaction and fibrosis degree, and is good in biological safety; in addition, according to drug concentration detection, it is proved that the film has the drug sustained release effect, the relative drug concentration can be maintained for a period of time after the operation, and the inflammatory reaction and the fibrosis degree are relieved. The thin film has good water reactivity and biodegradability at the same time, can be completely attached to heart tissue by means of intermolecular acting force after being wetted and does not adhere to the heart by means of viscidity, secondary damage to the tissue caused by tearing again is avoided, and the thin film can be completely degraded after being implanted into a living body for a certain time. In addition, compared with traditional anti-adhesion flushing fluid, the thin film can be cut according to needs and attached to the needed position, and the influence of excessive flushing on other tissue is avoided.

Description

Technical Field

[0001] The invention relates to the technical field of medical materials, and in particular to a drug-loaded artificial pericardium and a preparation method thereof. Background Art

[0002] In recent years, with the continuous advancement of cardiac surgical technology, the proportion of secondary operations has gradually increased, and adhesions have become an important factor affecting the effect of secondary operations. For example, in coronary artery bypass grafting, adhesions can lead to a significant increase in the incidence of severe complications related to bleeding.

[0003] At present, anti-adhesion materials can be divided into two categories: non-absorbable materials and bioabsorbable materials. Non-absorbable materials include artificial synthetic membranes and xenograft membranes. Among them, artificial synthetic membranes include silicone rubber, expanded polytetrafluoroethylene membranes, polyethylene films, polyester mesh, etc. Bioabsorbable materials include polylactic acid, carboxymethyl cellulose, hyaluronic acid films, etc.

[0004] The current non-absorbable materials used as anti-adhesion materials are permanent foreign bodies in the body and may cause inflammatory reactions in the body. The single film to prevent cardiac adhesion only plays an isolating role and has no good effect in promoting tissue healing, reducing myocardial fibrosis and inflammatory reactions, and improving cardiac function recovery. In addition, the current gel or film to prevent postoperative adhesion cannot be cut and attached as needed. Once the film adheres to the heart, it is difficult to tear it off, which may cause secondary damage to tissue contusion.

[0005] Chinese patent CN201711425189 discloses an absorbable anti-adhesion material for cardiac surgery and a membrane prepared therefrom. The isolation film is made of chitosan, gelatin, glycerol, collagen, and silk fibroin, has good biocompatibility, is absorbable and degradable, can prevent postoperative adhesion of the heart to surrounding tissues, and protect heart function. This anti-adhesion membrane can only play a single role in physically preventing adhesions, and does not have anti-inflammatory and antioxidant capabilities.

[0006] Chinese patent CN201310214708.2 discloses a wound flushing, anti-adhesion liquid for surgical operation, and its preparation method and application, which uses sodium carboxymethyl cellulose, brown algae oligosaccharide, hydroxyethyl starch, polyethylene glycol, and sodium chloride, and is mixed with injection water by stirring or cross-linking to form a film or liquid, which has multiple functions such as hemostasis, antibacterial, anti-adhesion, and healing promotion; this anti-adhesion flushing liquid cannot be flushed at a specific site as needed, and the flushing liquid may affect areas outside the surgical area, and does not have anti-inflammatory and antioxidant capabilities.

[0007] In view of this, the present invention is proposed. Summary of the invention

[0008] In order to solve the above technical problems, the present invention provides an artificial pericardium which can prevent postoperative tissue adhesion and reduce cardiac fibrosis and inflammatory response.

[0009] Specifically, the technical solution of the present invention is as follows: In a first aspect, the present invention provides a drug-loaded artificial pericardium, which is prepared from the following raw materials in parts by weight: 0.575-0.625 parts of polyethylene oxide (PEO), 0.09-0.11 parts of polyethylene glycol (PEG), 0.9-1.1 parts of α-cyclodextrin (α-CD), 0.160-0.240 parts of sodium carboxymethyl cellulose (NaCMC), and 0.005-0.015 parts of colchicine.

[0010] The materials used in the drug-loaded artificial pericardium provided by the present invention are all absorbable materials with good biocompatibility, are not likely to cause inflammatory reactions in the body, and can be degraded and absorbed; they can promote the recovery of the heart to a certain extent through a sustained release effect, and have a better effect on promoting tissue healing, reducing myocardial fibrosis and inflammatory reactions, and improving cardiac function recovery; they can also be cut as needed and attached to specific parts of the heart, and can completely wrap the heart after being moistened with water without bruising the tissue.

[0011] Preferably, the drug-loaded artificial pericardium is prepared from the following raw materials in parts by weight: 0.600 parts of polyethylene oxide, 0.1 parts of polyethylene glycol, 1.0 parts of α-cyclodextrin, 0.200 parts of sodium carboxymethyl cellulose, and 0.01 parts of colchicine.

[0012] Preferably, the molecular weight of polyethylene oxide is 1×10 6 -3×10 6 .

[0013] Preferably, the molecular weight of polyethylene glycol is 1500-2500.

[0014] In a second aspect, the present invention provides a method for preparing the drug-loaded artificial pericardium described in the first aspect, which comprises the following steps: adding α-cyclodextrin to a 50-70°C polyethylene glycol aqueous solution and mixing; then successively adding a polyethylene oxide aqueous solution and colchicine and mixing; after drying at 50-70°C for 12-24 hours, adding a sodium carboxymethyl cellulose aqueous solution on the surface of the mixture, and continuing to dry at 50-70°C for 12-24 hours.

[0015] The present invention uses α-cyclodextrin, polyethylene glycol, and polyethylene oxide as main materials for preparing a device for preventing postoperative cardiac adhesion, which has good water reactivity and complete tissue wrapping, and can be tailored as needed; the present invention uses colchicine as a drug loaded by an artificial pericardium, which can release the drug efficacy through a film to reduce the degree of cardiac fibrosis and inflammatory response; the present invention prepares a double-layer artificial pericardium, uses NaCMC as an outer physical isolation layer, prevents adhesion between the heart and surrounding tissues, and releases drugs in the inner layer to promote cardiac function recovery.

[0016] Preferably, the mass fraction of the polyethylene oxide aqueous solution is 3.5%-4.5%.

[0017] Preferably, the mass fraction of the polyethylene glycol aqueous solution is 1.5%-2.5%.

[0018] Preferably, the mass fraction of the sodium carboxymethyl cellulose aqueous solution is 1.6%-2.4%.

[0019] More preferably, the preparation method comprises the following steps: adding 0.575-0.625 parts by mass of a 1×10 6 -3×10 6 The polyethylene oxide is dissolved in 14-16 parts by volume of ultrapure water to prepare a polyethylene oxide aqueous solution with a mass fraction of 3.5%-4.5%; 0.09-0.11 parts by volume of polyethylene glycol with a molecular weight of 1500-2500 is dissolved in 4-6 parts by volume of ultrapure water, vortexed and mixed, and then 0.9-1.1 parts by mass of α-cyclodextrin is slowly added in a 55-65°C water bath to dissolve, and ultrasonically bathed in 55-65°C water for 50-70s to obtain a mixture of polyethylene oxide and α-cyclodextrin; and then 14-16 parts by volume of a polyethylene oxide aqueous solution with a mass fraction of 3.5%-4.5% is added to prepare α - a mixed solution of cyclodextrin, polyethylene oxide and polyethylene glycol; then adding 0.005-0.015 parts by mass of colchicine, using a mixing and degassing machine at 1500-2500 rpm for centrifugal stirring for 1.5-2.5 minutes, repeating 2-4 times to obtain a thick mixture; adding the thick mixture to a glass-bottomed culture dish, sealing it in a 55-65°C oven overnight to remove bubbles in the mixture; then adding 4-6 parts by volume of a 1.6%-2.4% sodium carboxymethyl cellulose solution on the surface of the mixture, and placing it in a 55-65°C oven to dry overnight; wherein the ratio of the parts by mass to the parts by volume is g:mL.

[0020] The preparation method provided by the present invention is simple, and the prepared drug-loaded artificial pericardium has good biocompatibility, is absorbable and degradable, is convenient to implement (water-responsive and can be trimmed as needed), and can reduce cardiac fibrosis and inflammatory response.

[0021] Beneficial effects: The present invention provides a drug-loaded artificial pericardium and a preparation method thereof. The drug-loaded artificial pericardium provided by the present invention can be used to reduce adhesion between the heart and surrounding tissues after cardiac surgery and reduce postoperative inflammatory reactions and fibrosis. By comparing the experimental group and the control group 28 days after simulated myocardial infarction in an animal experiment, it was found that the film of the present invention has the effect of reducing cardiac adhesion, and according to the in vitro cell experiment, the biosafety of the film and the ability of the anti-adhesion layer to resist fibroblast adhesion are proved. In addition, according to the drug concentration test, it is proved that the film has the effect of sustained drug release, and can maintain a relative drug concentration for a period of time after surgery, reducing inflammatory reactions and fibrosis. The film of the present invention also has good water reactivity and biodegradability. After wetting, it can rely on intermolecular forces to completely adhere to the heart tissue, and does not rely on viscosity to adhere to the heart, avoiding secondary damage to the tissue caused by tearing again, and can be completely degraded within a certain period of time after implantation in the organism. In addition, compared with the traditional anti-adhesion flushing solution, the film can be cut as needed and attached to the required part to avoid the influence of excessive flushing on other tissues. BRIEF DESCRIPTION OF THE DRAWINGS

[0022] In order to more clearly illustrate the technical solutions in the present invention or the prior art, the drawings required for use in the embodiments or the description of the prior art will be described below.

[0023] Figure 1 The anti-adhesion results of the artificial pericardium in Experimental Example 1 of the present invention are shown in FIG.

[0024] Figure 2 This is the drug release curve of the artificial pericardium in Experimental Example 1 of the present invention.

[0025] Figure 3 This is an electron microscope image of the artificial pericardium in Experimental Example 1 of the present invention.

[0026] Figure 4 This is the water responsiveness result of the artificial pericardium in Experimental Example 1 of the present invention.

[0027] Figure 5 This is the biological safety result of the artificial pericardium in Experimental Example 1 of the present invention.

[0028] Figure 6 This is the degradability result of the artificial pericardium in the invention experiment example 1.

[0029] Figure 7 The figure shows the manufacturing process and the physical picture of the artificial pericardium of the present invention. DETAILED DESCRIPTION

[0030] In order to prevent tissue adhesion after cardiac surgery, the present invention provides an artificial pericardium with good biocompatibility, absorbable and degradable, convenient implementation (water responsiveness and trimmable as needed), and the functions of reducing cardiac fibrosis and inflammatory response.

[0031] The present invention adopts the following technical solutions: An artificial pericardium that can prevent postoperative tissue adhesion and reduce cardiac fibrosis and inflammatory response, wherein the membrane prepared by the material comprises the following raw materials: α-cyclodextrin (α-CD), polyethylene glycol (PEG), polyethylene oxide (PEO), sodium carboxymethyl cellulose (NaCMC), and colchicine. All materials are absorbable and degradable materials with good biocompatibility and will not cause autoinflammatory response.

[0032] The artificial pericardium provided by the present invention uses α-CD, PEG, and PEO as main materials for preparing the inner layer of the film, wherein α-CD and PEG serve as the skeleton part of the film, and PEO serves as the cross-linking part of the film. After preparation, the film can be cut as needed and has good water reactivity. After being wetted by water, the film can shrink and completely wrap the attached tissue, and will not cause contusion to the tissue after being uncovered.

[0033] The artificial pericardium provided by the present invention uses NaCMC as the material for preparing the outer layer of the film. NaCMC can provide a physical isolation layer for the tissue to prevent the fibrin produced by the surrounding tissue from adhering to the heart, and can effectively prevent the occurrence of postoperative cardiac adhesion. In addition, NaCMC has good biocompatibility with the tissue and will not cause autoinflammatory reaction.

[0034] In one of the more specific and preferred embodiments provided by the present invention, the preparation method is: 0.600 g of a molecular weight of 2×10 6 Dissolve PEO in 15 mL ultrapure water to prepare 15 mL of PEO solution with a mass fraction of 4%. Dissolve 0.1 g of PEG with a molecular weight of 2000 in 5 mL of ultrapure water, vortex and mix well, then slowly add 1 g of α-CD to dissolve in a 60°C water bath, ultrasonically bathe in 60°C water for 1 minute to obtain a PEG-α-CD mixture, then add 15 mL of a 4% PEO solution to make an α-CD / PEG / PEO solution, add 10 mg of colchicine, use a mixing degassing machine to centrifuge and stir for 2 minutes at 2000 rpm, and repeat twice. Add the resulting thick mixture to a glass-bottomed culture dish, seal it in a 60°C oven overnight (12 hours), and remove bubbles in the mixture. Then add 10 mL of 2% NaCMC solution to the surface of the mixture, put it in a 60°C oven and dry it overnight (12 hours) to obtain the final drug-loaded artificial pericardium product. The artificial pericardium provided by the present invention uses colchicine as the drug loaded in the inner layer of the film, which can effectively reduce the degree and area of ​​cardiac fibrosis after surgery or myocardial infarction, help restore cardiac function, and also help reduce cardiac inflammatory response and reduce adhesion between the heart and surrounding tissues after surgery.

[0035] In order to make the purpose, technical solution and advantages of the present invention clearer, the technical solution of the present invention will be described clearly and completely below. Obviously, the described embodiments are part of the embodiments of the present invention, not all of the embodiments. Based on the embodiments of the present invention, all other embodiments obtained by ordinary technicians in this field without creative work are within the scope of protection of the present invention.

[0036] The endpoints and any values ​​of the ranges disclosed in this specification are not limited to the precise ranges or values, and these ranges or values ​​should be understood to include values ​​close to these ranges or values. For numerical ranges, the endpoint values ​​of each range, the endpoint values ​​of each range and the individual point values, and the individual point values ​​can be combined with each other to obtain one or more new numerical ranges, which should be considered as specifically disclosed in this article.

[0037] In the description of this specification, the description with reference to the terms "one embodiment", "some embodiments", "specific implementations", or "some specific implementations" etc. means that the specific features, structures, materials or characteristics described in conjunction with the embodiment or example are included in at least one embodiment or example of the embodiment of the present invention. In this specification, the schematic representations of the above terms do not necessarily refer to the same embodiment or example. Moreover, the specific features, structures, materials or characteristics described may be combined in any one or more embodiments or examples in a suitable manner. In addition, those skilled in the art may combine and combine the different embodiments or examples described in this specification and the features of the different embodiments or examples, without contradiction.

[0038] In the examples provided in this specification, if no specific techniques or conditions are specified, the techniques or conditions described in the literature in this field or the product instructions are used. If the manufacturer of the reagents or instruments used is not specified, they are all conventional products that can be purchased through regular channels.

[0039] Example 1 This embodiment provides a drug-loaded artificial pericardium that can prevent postoperative tissue adhesion and reduce cardiac fibrosis and inflammatory response, and the preparation method thereof is as follows: 0.600g of molecular weight is 2×10 6Dissolve PEO in 15 mL ultrapure water to prepare 15 mL of PEO solution with a mass fraction of 4%. Dissolve 0.1 g of PEG with a molecular weight of 2000 in 5 mL of ultrapure water, vortex and mix well, then slowly add 1 g of α-CD to dissolve in a 60°C water bath, ultrasonically bathe in 60°C water for 1 minute to obtain a PEG-α-CD mixture, then add 15 mL of PEO solution with a mass fraction of 4% to prepare an α-CD / PEG / PEO solution, add 10 mg of colchicine, use a mixing degasser to centrifuge and stir for 2 minutes at 2000 rpm, and repeat twice. Add the resulting thick mixture to a glass-bottomed culture dish, seal it in a 60°C oven overnight (12 hours), and remove bubbles in the mixture. Then add 10 mL of 2% NaCMC solution to the surface of the mixture, put it in a 60°C oven and dry it overnight (12 hours) to obtain the final drug-loaded artificial pericardium product.

[0040] Example 2 This embodiment provides a drug-loaded artificial pericardium that can prevent postoperative tissue adhesion and reduce cardiac fibrosis and inflammatory response, and the preparation method thereof is as follows: 0.625 g of molecular weight is 3×10 6 PEO was dissolved in 16 mL of ultrapure water to prepare 16 mL of PEO solution with a mass fraction of 3.9%. 0.11 g of PEG with a molecular weight of 2000 was dissolved in 5.5 mL of ultrapure water, vortexed and mixed, and then 1.1 g of α-CD was slowly added to dissolve in a 65°C water bath, ultrasonically bathed in 65°C water for 1 minute to obtain a PEG-α-CD mixture, and then 16 mL of PEO solution with a mass fraction of 3.9% was added to make an α-CD / PEG / PEO solution, and then 10 mg of colchicine was added. The mixture was centrifuged and stirred at 2000 rpm using a mixing degassing machine for 2 minutes, and repeated 3 times. The resulting thick mixture was added to a glass-bottomed culture dish, sealed in a 65°C oven overnight (12 hours) to remove bubbles in the mixture. Then 10 mL of 2% NaCMC solution was added to the surface of the mixture, and the mixture was dried in a 65°C oven overnight (12 hours) to obtain the final drug-loaded artificial pericardium product.

[0041] Example 3 This embodiment provides a drug-loaded artificial pericardium that can prevent postoperative tissue adhesion and reduce cardiac fibrosis and inflammatory response, and the preparation method thereof is as follows: 0.575 g of molecular weight is 2×10 6Dissolve PEO in 14 mL ultrapure water to prepare 14 mL of PEO solution with a mass fraction of 4.1%. Dissolve 0.09 g of PEG with a molecular weight of 2000 in 4.5 mL of ultrapure water, vortex and mix well, then slowly add 0.9 g of α-CD to dissolve in a 60°C water bath, ultrasonically bath in 55°C water for 1 minute to obtain a PEG-α-CD mixture, then add 14 mL of PEO solution with a mass fraction of 4.1% to prepare an α-CD / PEG / PEO solution, add 10 mg of colchicine, use a mixing degasser to centrifuge and stir for 2 minutes at 2000 rpm, and repeat 3 times. Add the resulting thick mixture to a glass-bottomed culture dish, seal it in a 55°C oven overnight (12 hours), and remove bubbles in the mixture. Then add 10 mL of 2% NaCMC solution to the surface of the mixture, put it in a 55°C oven and dry it overnight (12 hours) to obtain the final drug-loaded artificial pericardium product.

[0042] Experimental Example 1 In this experimental example, the drug-loaded artificial pericardium prepared in Example 1 was used as the experimental material to test its anti-adhesion ability, drug release concentration, microstructure, water reaction characteristics, biosafety, and degradability.

[0043] The specific detection methods are as follows: Anti-adhesion ability: The myocardial infarction model was established by ligating the anterior descending branch of the mouse coronary artery, and a cut artificial pericardium patch was implanted in the ligated area. After 28 days of implantation, the group was photographed and compared with the non-implanted group to observe the adhesion effect between the heart and surrounding tissues.

[0044] Drug release concentration: Place the artificial pericardium in a 24-well Transwell chamber with the drug-carrying layer facing downward to simulate the release of drugs by the artificial pericardium attached to the heart surface. Add ultrapure water to the lower well plate of the chamber, and measure the absorbance of the solution in the well plate every 1 day, 2 days, 3 days, and 4 days. Prepare a colchicine standard concentration reagent, measure its absorbance, obtain a colchicine absorbance-concentration standard curve, substitute the measured absorbance to obtain the drug release concentration on different days, and draw a drug release curve.

[0045] Microstructure: Take a 1mmX1mm artificial pericardium and stick it on the sample stage with conductive tape, and use a scanning electron microscope to observe its microscopic double-layer film structure.

[0046] Water reaction characteristics: The prepared artificial pericardium was cut into a rectangle of 1 cm x 0.5 cm, placed in a culture dish filled with ultrapure water, and the reaction of the film after contact with water was observed within an instant.

[0047] Biosafety: Primary mouse fibroblasts were transplanted onto 6-well plates containing artificial pericardium and without membrane to form the experimental group and the control group, respectively. The cells were stained with F-actin and DAPI by immunofluorescence to observe the cell growth status.

[0048] Degradability: Artificial pericardium was implanted on the surface of mouse heart, and the chest was opened after 7 days to observe the degradation of the artificial pericardium.

[0049] Test results are shown in Figure 1-6 .

[0050] Depend on Figure 1 It can be seen that the adhesion between the heart and surrounding tissues in the experimental group implanted with artificial pericardium was less severe than that in the control group without treatment.

[0051] Depend on Figure 2 It can be seen that the drug concentration of the drug-loaded artificial pericardium gradually reaches equilibrium within 4 days, indicating the drug sustained-release effect of the film.

[0052] Depend on Figure 3 It can be seen that the artificial pericardium has a double-layer structure under a scanning electron microscope. The drug-loading layer has a loose structure, which is conducive to drug release, and the anti-adhesion layer has a dense structure, which can prevent drug release and ensure the directional release of colchicine to a certain extent.

[0053] Depend on Figure 4 It can be seen that the artificial pericardium reacts quickly to water and shrinks within 2 seconds, which shows that the film has rapid water responsiveness and can quickly adhere to the tissue on the moist heart surface.

[0054] Depend on Figure 5 It can be seen that the cells grow well on the artificial pericardium, and compared with the control group, the cardiac fibroblasts on the artificial pericardium are less attached, and the anti-fibroblast adhesion ability of the film reflects its anti-adhesion property.

[0055] Depend on Figure 6 It can be seen that 7 days after the artificial pericardium was implanted on the surface of the heart, most of the film was degraded, proving its degradability.

[0056] Finally, it should be noted that the above embodiments are only used to illustrate the technical solutions of the present invention, rather than to limit it. Although the present invention has been described in detail with reference to the aforementioned embodiments, those skilled in the art should understand that they can still modify the technical solutions described in the aforementioned embodiments, or make equivalent replacements for some of the technical features therein. However, these modifications or replacements do not deviate the essence of the corresponding technical solutions from the spirit and scope of the technical solutions of the embodiments of the present invention.

Claims

1. A drug-loaded artificial pericardium, characterized in that: The invention is prepared from the following raw materials in parts by weight: 0.575-0.625 parts of polyethylene oxide, 0.09-0.11 parts of polyethylene glycol, 0.9-1.1 parts of alpha-cyclodextrin, 0.160-0.240 parts of sodium carboxymethyl cellulose and 0.005-0.015 parts of colchicine.

2. The drug-loaded artificial pericardium according to claim 1, characterized in that: The preparation method is prepared from the following raw materials in parts by weight: 0.600 parts of polyethylene oxide, 0.1 parts of polyethylene glycol, 1.0 parts of α-cyclodextrin, 0.200 parts of sodium carboxymethyl cellulose, and 0.01 parts of colchicine.

3. The drug-loaded artificial pericardium according to claim 1 or 2, characterized in that: The molecular weight of polyethylene oxide is 1×10 6 -3×10 6 .

4. The drug-loaded artificial pericardium according to any one of claims 1 to 3, characterized in that: The molecular weight of polyethylene glycol is 1500-2500.

5. The method for preparing the drug-loaded artificial pericardium according to any one of claims 1 to 4, characterized in that: The method comprises the following steps: adding α-cyclodextrin to a polyethylene glycol aqueous solution at 50-70°C and mixing; then successively adding a polyethylene oxide aqueous solution and colchicine and mixing; drying at 50-70°C for 12-24 hours, adding a sodium carboxymethyl cellulose aqueous solution on the surface of the mixture, and continuing to dry at 50-70°C for 12-24 hours.

6. The preparation method according to claim 6, characterized in that: The mass fraction of the polyethylene oxide aqueous solution is 3.5%-4.5%.

7. The preparation method according to claim 5 or 6, characterized in that: The mass fraction of the polyethylene glycol aqueous solution is 1.5%-2.5%.

8. The preparation method according to any one of claims 5 to 7, characterized in that: The mass fraction of the sodium carboxymethyl cellulose aqueous solution is 1.6%-2.4%, preferably 2.0%.

9. The preparation method according to any one of claims 5 to 8, characterized in that: The steps include: adding 0.575-0.625 parts by weight of a 1×10 6 -3×10 6 The polyethylene oxide is dissolved in 14-16 parts by volume of ultrapure water to prepare a polyethylene oxide aqueous solution with a mass fraction of 3.5%-4.5%; 0.09-0.11 parts by volume of polyethylene glycol with a molecular weight of 1500-2500 is dissolved in 4-6 parts by volume of ultrapure water, vortexed and mixed, and then 0.9-1.1 parts by mass of α-cyclodextrin is slowly added in a 55-65°C water bath to dissolve, and ultrasonically bathed in 55-65°C water for 50-70s to obtain a mixture of polyethylene oxide and α-cyclodextrin; and then 14-16 parts by volume of a polyethylene oxide aqueous solution with a mass fraction of 3.5%-4.5% is added to prepare α - a mixed solution of cyclodextrin, polyethylene oxide and polyethylene glycol; then adding 0.005-0.015 parts by mass of colchicine, using a mixing and degassing machine at 1500-2500 rpm for centrifugal stirring for 1.5-2.5 minutes, repeating 2-4 times to obtain a thick mixture; adding the thick mixture to a glass-bottomed culture dish, sealing it in a 55-65°C oven overnight to remove bubbles in the mixture; then adding 4-6 parts by volume of a 1.6%-2.4% sodium carboxymethyl cellulose solution on the surface of the mixture, and placing it in a 55-65°C oven to dry overnight; wherein the ratio of the parts by mass to the parts by volume is g:mL.

10. A drug-loaded artificial pericardium, characterized in that: The compound is prepared by the preparation method described in any one of claims 5 to 9.

Images